EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Nanomedicine in Ovarian Cancer: Advances in Imaging, Targeted Delivery, and Theranostic Therapeutic Platforms

Dorota Bartusik-Aebisher iD, Izabella Wilk iD, David Aebisher iD

Cancers · 27.12.2025 · 18 (1) · 86

DOI: 10.3390/cancers18010086 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 27.12.2025. Verfasst von Dorota Bartusik-Aebisher und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and General Chemistry, Collegium Medicum, Faculty of Medicine, University of Rzeszów, 35-310 Rzeszów, Poland. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 220 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian cancer continues to be the most lethal gynaecological malignancy, principally due to its late-stage diagnosis, extensive peritoneal dissemination, chemoresistance, and limitations of current imaging and therapeutic strategies. By optimising pharmacokinetics, refining tumour-selective drug delivery, and supporting high-resolution, multimodal imaging, nanomedicine offers a versatile platform to address these limitations. In this review, current progress across lipid-based, polymeric, inorganic, hybrid, and biomimetic nanocarriers is synthesised, emphasising how tailored physiochemical properties, surface functionalisation, and stimuli-responsive designs can improve tumour localisation, surmount stromal and ascetic barriers, and enable controlled drug release. Concurrently, significant advancement in imaging nanoprobes, including magnetic resonance imaging (MRI), positron emission tomography (PET)/single-photon emission computed tomography (SPECT), optical, near-infrared imaging (NIR), ultrasound, and photoacoustic systems, has evolved early lesion detection, intraoperative guidance, and quantitative monitoring of treatment. Diagnosis and therapy are further integrated within single platforms by emerging theranostic constructs, encouraging real-time visualisation of drug distribution and treatment response. Additionally, immune-nanomedicine, intraperitoneal depot systems, and nucleic acid-centred nanotherapies offer promising strategies to address immune suppression and molecular resistance in advanced ovarian cancer. In spite of noteworthy achievements, clinical translation is limited by complex manufacturing requirements, challenges with safety and stability, and restricted patient stratification. To unlock the full clinical potential of nanotechnology in ovarian cancer management, constant innovation in scalable design, regulatory standardisation, and integration of precision biomarkers will be necessary.

Schlagwörter

Stichwörter der Autor:innen

intraperitoneal nanotherapymultimodal imagingovarian cancer nanomedicinestimuli-responsive nanocarrierstargeted drug deliverytheranostic nanoparticlestheranostic therapeutic platformstumour microenvironment (TME) targeting

Autor:innen und Institutionen

  • Department of Biochemistry and General Chemistry, Collegium Medicum, Faculty of Medicine, University of Rzeszów, 35-310 Rzeszów, Poland.
  • English Division Science Club, Collegium Medicum, Faculty of Medicine, University of Rzeszów, 35-310 Rzeszów, Poland.
  • Department of Photomedicine and Physical Chemistry, Collegium Medicum, Faculty of Medicine, University of Rzeszów, 35-310 Rzeszów, Poland.

ORCID-Profile: Dorota Bartusik-Aebisher, Izabella Wilk, David Aebisher

Zitieren

APA

Bartusik-Aebisher, D., Wilk, I., & Aebisher, D. (2025). Nanomedicine in Ovarian Cancer: Advances in Imaging, Targeted Delivery, and Theranostic Therapeutic Platforms. Cancers, 18(1), 86. https://doi.org/10.3390/cancers18010086

Vancouver

Bartusik-Aebisher D, Wilk I, Aebisher D. Nanomedicine in Ovarian Cancer: Advances in Imaging, Targeted Delivery, and Theranostic Therapeutic Platforms. Cancers. 2025;18(1):86. doi:10.3390/cancers18010086

BibTeX
@article{BartusikAebisher2025,
  author = {Bartusik-Aebisher, Dorota and Wilk, Izabella and Aebisher, David},
  title = {Nanomedicine in Ovarian Cancer: Advances in Imaging, Targeted Delivery, and Theranostic Therapeutic Platforms},
  journal = {Cancers},
  year = {2025},
  volume = {18},
  number = {1},
  pages = {86},
  doi = {10.3390/cancers18010086}
}
Kostenlos starten →